share_log

RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price Target

Benzinga ·  Dec 6 00:05  · Ratings

RBC Capital analyst Gregory Renza reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $44 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment